Advertisement
Case Report| Volume 19, ISSUE 2, 104484, February 2023

A Rare Case of MDMA-Induced Hyponatremia

Published:November 19, 2022DOI:https://doi.org/10.1016/j.nurpra.2022.10.013

      Highlights

      • Use of psychedelic drugs, including 3,4 methylenedioxymethamphetamine (MDMA; aka “Ecstasy” or “Molly”) is increasing as emerging research suggests they may be effective treatments for mental health concerns, including depression, anxiety, posttraumatic stress disorder, and addiction
      • Hyponatremia is a rare adverse effect of MDMA use.
      • Hyponatremia may have serious complications if not treated quickly and appropriately. Treatment differs depending on cause, symptoms, and severity.

      Abstract

      Hyponatremia is a common, potentially serious problem encountered in primary, acute, and critical care settings. Proper treatment requires an understanding of the multiple possible causes of hyponatremia. This case report presents an unusual cause of hyponatremia—3,4 methylenedioxymethamphetamine (MDMA; “Ecstasy” or “Molly”) use. With encouraging research emerging on the use of psychedelic drugs to treat depression, anxiety, posttraumatic stress disorder, and addiction, nurse practitioners should increase their knowledge about the evolution of MDMA from a recreational drug to a potential medicine for the care of people with serious and persistent mental health concerns.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Penn A.
        • Dorsen C.G.
        • Hope S.
        • Rosa W.E.
        Psychedelic-assisted therapy: emerging treatments in mental health disorders.
        Am J Nurs. 2021; 121: 34-40
        • Feduccia A.A.
        • Jerome L.
        • Yazar-Klosinski B.
        • Emerson A.
        • Mithoefer M.C.
        • Doblin R.
        Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline.
        Front Psychiatry. 2019; 10: 650
        • McIntyre R.S.
        • Rosenblat J.D.
        • Nemeroff C.B.
        • et al.
        Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.
        Am J Psychiatry. 2021; 178: 383-399
        • Krebs T.S.
        • Johansen P.Ø.
        Over 30 million psychedelic users in the United States.
        F1000Res. 2013; 2: 98https://doi.org/10.12688/f1000research.2-98.v1
        • National Institutes of Health
        National Institute on Drug Abuse. Marijuana and hallucinogen use among young adults reached all time-high in 2021.
        (August 22)
        • Dorsen C.
        • Palamar J.
        • Shedlin M.G.
        Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study.
        Addict Res Theory. 2019; 27: 68-75
        • Johnson M.W.
        • Griffiths R.R.
        • Hendricks P.S.
        • et al.
        The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
        Neuropharmacology. 2018; 142: 143-166
        • Kopra E.I.
        • Ferris J.A.
        • Winstock A.R.
        • Young A.H.
        • Rucker J.J.
        Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
        J Psychopharmacol. 2022; 36: 965-973https://doi.org/10.1177/02698811221084063
        • Carhart-Harris R.L.
        • Nutt D.J.
        Experienced drug users assess the relative harms and benefits of drugs: a web-based survey.
        J Psychoactive Drugs. 2013; 45: 322-328
        • Nutt D.J.
        • King L.A.
        • Phillips L.D.
        Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis.
        Lancet. 2010; 376: 1558-1565
        • Schröder A.S.
        • Andresen-Streichert H.
        • Anders S.
        Swollen lips after a night of partying-an allergic reaction to Ecstasy?.
        J Forensic Sci. 2019; 64: 1281-1282
        • Jahns F.P.
        • Pineau Mitchell A.
        • Auzinger G.
        Too hot to handle: a case report of extreme pyrexia after MDMA ingestion.
        Ther Hypothermia Temp Manag. 2018; 8: 173-175
        • Ghaffari-Rafi A.
        • Eum K.S.
        • Villanueva J.
        • Jahanmir J.
        Protracted hyperthermia and delayed rhabdomyolysis in ecstasy toxicity: a case report.
        Medicine (Baltimore). 2020; 99e21842
        • Salathe C.
        • Blanc A.L.
        • Tagan D.
        SIADH and water intoxication related to ecstasy.
        BMJ Case Rep. 2018; 2018bcr2018224731
        • National Institutes of Health
        National Institute of Mental Health. Psychedelics as Therapeutics: Gaps, Challenges and Opportunities.
        (January 12–13)
        • Hoorn E.J.
        • Zietse R.
        Hyponatremia and mortality: moving beyond associations.
        Am J Kidney Dis. 2013; 62: 139-149
        • Sterns R.
        Causes of hypotonic hyponatremia in adults. UpToDate.
        • Hoorn E.J.
        • Zietse R.
        Diagnosis and treatment of hyponatremia: compilation of the guidelines.
        J Am Soc Nephrol. 2017; 28: 1340-1349
        • Rondon H.
        • Badireddy M.
        Hyponatremia.
        (Updated January 31, 2022. StatPearls. StatPearls Publishing)
        • Hoffman R.J.
        MDMA (ecstasy) intoxication.
        (Updated March 3, 2022. UpToDate)
        • Moritz M.L.
        • Kalantar-Zadeh K.
        • Ayus J.C.
        Ecstacy-associated hyponatremia: why are women at risk?.
        Nephrol Dial Transplant. 2013; 28: 2206-2209https://doi.org/10.1093/ndt/gft192
        • Yeates K.E.
        • Singer M.
        • Morton A.R.
        Salt and water: a simple approach to hyponatremia.
        CMAJ. 2004; 170 (Published correction appears in CMAJ. 2004;170(6):931): 365-369
        • Sahay M.
        • Sahay R.
        Hyponatremia: a practical approach.
        Indian J Endocrinol Metab. 2014; 18: 760-771https://doi.org/10.4103/2230-8210.141320
        • Rondon-Berrios H.
        • Berl T.
        Mild chronic hyponatremia in the ambulatory setting: significance and management.
        Clin J Am Soc Nephrol. 2015; 10: 2268-2278

      Biography

      Carolina Dorsen, PhD, FNP-BC, is an associate professor and associate dean, Rutgers University School of Nursing, Newark, NJ, and can be contacted at [email protected]

      Biography

      Andrew Penn, MS, PMHNP-Bc, is an associate professor of Community Health Systems University of California, San Francisco School of Nursing.

      Biography

      Natasha Carew, DNP, ACNP-BC, is an assistant professor at Rutgers University School of Nursing, Newark, NJ.

      Biography

      Madeleine Lloyd, PhD, FNP-BC, PMHNP-BC, is affiliated with New York University Langone Health, New York, NY.